Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer

Trial Profile

Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Oropharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 14 Nov 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2018.
    • 14 Nov 2017 Status changed from suspended to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top